DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS 📋 Regulatory Action / Label Change
The FDA approved a new subcutaneous furosemide delivery system for adults with edema related to heart failure or chronic kidney disease. The autoinjector reduces administration time from approximately five hours to less than ten seconds while achieving IV-equivalent exposure.
Professional Impact
- Furoscix ReadyFlow delivers 80 mg/mL furosemide via subcutaneous autoinjector in approximately 10 seconds.
- Clinical data demonstrated comparable urine output and sodium and potassium excretion versus intravenous furosemide.
- MannKind positions the product for outpatient, post-discharge, and home-based management of fluid overload.
- Approval expands a platform previously available through an on-body infusor requiring approximately five hours of administration.
Action Items
- Review appropriate patient selection for outpatient diuretic escalation.
- Evaluate potential roles in transitional and post-discharge heart failure care.
- Monitor electrolyte depletion, hypotension, and volume status after administration.
- Update care pathways as availability and coverage information emerge.
